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Summary The current work was undertaken to investigate the importance of exposure sequence and duration
in achieving the maximum reversal action of S9788 on doxorubicin (DOX) cytotoxicity against cells that
exhibit the (MDR) multidrug resistance phenotype: the MCF7/DOX cell line. Accumulation and release of
DOX were examined in this cell line. The reversal effect was compared with that obtained with verapamil.
S9788 activity was schedule dependent: when comparing incubation with S9788 before or after treatment with
DOX, the best reversal factor was obtained in the case of a post-treatment incubation (65.6 ± 7.7 vs
20.8 ± 7.0). S9788 was a more potent modulating agent than verapamil, whatever the schedule of exposure of
the cells to the reversal agent. The reversal of resistance after short-term DOX exposures was caused not only
by prolonged cellular accumulation of DOX, but also by its prolonged retention after transfer of cells to
DOX-free medium. A relationship was noted between cellular exposure to DOX and the cytotoxic effect, and
so the reversal of resistance induced by S9788 appears to be directly linked to the level of cell exposure to
DOX. This work provided a rationale for improving the schedule of administration of S9788 in clinical
trials.
The development of resistance of human cancers to potent
anti-cancer agents has been classically ascribed to the selec-
tion and outgrowth of a pre-existing or newly emerging
subpopulation of resistant tumour cells (Coldman & Goldie,
1985, Carl, 1989). Great progress in the understanding of the
mechanism of one type of in vitro-derived resistance, so-
called multidrug resistance (MDR), was recently achieved by
the successful cloning of the mdrl gene, which encodes a
170 kDa plasma membrane protein called P-glycoprotein
(Pgp) (Gottesman & Pastan, 1988).
A wide variety of compounds have now been shown to
reverse MDR in vitro, including calcium channel antagonists
(verapamil and analogues; Tsuruo et al., 1982, 1983), cal-
modulin antagonists (trifluoperazines and analogues;
Ganapathi & Grabowski, 1983; Akiyama et al., 1986),
steroids (progesterone), immunomodulators (cyclosporin A
and analogues; Twentyman, 1988), antimalarial drugs
(quinine, quinidine; Tsuruo et al., 1984), oestrogen receptor
inhibitors (tamoxifen, toremifene; Ramu et al., 1984, De
Gregorio et al., 1989), and others. Verapamil (Ozols et al.,
1987; Pennock et al., 1991), cyclosporin A (Yahanda et al.,
1992) and quinine (Solary et al., 1992) have been used in
early clinical trials, but results have been disappointing so
far, one cause probably being the impossibility of sufficient
dose escalation owing to the prohibitive toxicity of the rever-
sal agent.
The search for novel and more potent modulators of the
MDR phenotype that are not limited by side-effects is
therefore of major importance. S9788 is a novel triazino-
aminopiperidine derivative which has demonstrated potent
reversal of the MDR phenotype in vitro and in vivo
(Dhainaut et al., 1992). It induces a dose-dependent increase
in doxorubicin (DOX) accumulation. It is twice as active and
approximately seven times more potent than verapamil
(Leonce et al., 1992; Pierre et al., 1992). In vivo, S9788
restored the anti-tumour activity of vincristine in a dose-
dependent manner in the P388/VCR leukaemia model (Cros
et al., 1992).
The current work was undertaken to investigate the impor-
tance of exposure sequence and duration in achieving the
maximal reversal action of S9788 on DOX cytotoxicity
against cells that exhibit the MDR phenotype: the MCF7/
DOX cell line. This reversal effect was compared with that of
verapamil, which is considered to be the reference compound.
The effects of various exposure schedules (simultaneous or
sequential incubation) on clonogenic assay and on accumula-
tion and release of DOX were examined in the MCF7/DOX
cell line (900-fold resistant to DOX) compared with the
sensitive cell line.
Materials and methods
Drugs
Doxorubicin (DOX) was obtained from Farmitalia Carlo
Erba (Rueil-Malmaison, France) and was dissolved in sterile
water to a final concentration of 2 mg ml-'. The clinical
formulation of verapamil (VRP, Isoptine) was purchased
from Biosedra (Malakoff, France). S9788 (6-4-[2,2-di(4-
fluorophenyl)ethylamino]piperidinl-yl N,N'-dipropen-2-yl 1,3,5-
triazine 2,4-diamine, bismethanesulphonate) was synthesised at
the Servier Research Institute (Courbevoie, France). It was
dissolved in sterile water at a concentration of 10mgml-'
and aliquots were stored at -20°C. For cell treatments,
drugs were further diluted in culture medium.
Cell lines
The MCF7 human mammary cell line was obtained from
ATCC (Rockville Pike, USA). The doxorubicin-resistant sub-
line MCF7/DOX (kindly provided by Dr J. Robert,
Bordeaux, France) was obtained by continuous exposure to
doxorubicin and was characterised by Batist et al. (1986).
The MCF7 and MCF7/DOX cell lines were grown in RPMI-
1640 medium supplemented with 10% fetal calf serum (Tech-
gen, Les Ulis, France). A selection pressure of 10JIM DOX
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was constantly maintained in the culture medium of the
DOX-resistant cell line. Twenty-four hours before experi-
ments, DOX was removed.
Cell survival studies
Cytotoxicity was measured by clonogenic test. Viability was
defined as the ability of single cells to give rise to a colony of
50 cells. Two types of control cultures were included in each
experiment: one consisted of cells incubated without any
drugs and the other evaluated the effects of the MDR
modulator on cell viability without DOX. The conditions of
the clonogenic assay were dependent on the doubling time of
the cell line: 24 h and 36 h for the MCF7 and MCF7/DOX
cell lines respectively. Cell suspension aliquots (900 cells for
MCF7 and 1,500 cells for MCF7/DOX) were seeded into
25 cm2 flasks and incubated at 37°C in a 5% carbon dioxide
atmosphere in air. Cells were treated 24 h after plating. The
ranges of DOX concentrations used for IC50 determinations
were 0.01-2 t4M for MCF7 and 0.2-700ylM for MCF7/DOX.
After drug treatments, the medium was discarded and
replaced by fresh RPMI-1640 medium. Colonies appeared
after 10 days of incubation for MCF7 and 21 days for
MCF7/DOX. The colonies were fixed with a 10% trichlor-
acetic acid solution and stained with 10% Giemsa and
counted. Three independent experiments were performed in
triplicate.
Schedules
To measure the reversal activity of modulators, cells were
incubated for 1 h with different concentrations of DOX
either alone or with 1 JLM S9788 or VRP. The concentration
of 1 gkM was chosen as experimental data showed that this
concentration has no cytotoxic effect on cells and clinical
data demonstrated that this concentration is achievable in
clinical situations with S9788 or VRP (Lucas et al., 1993) or
VRP (Ozols et al., 1987; Cairo et al., 1989). MCF7 and
MCF7/DOX cells were subjected to different treatment
schedules (Table I):
1. Cells were exposed for 1 h to DOX alone.
2. Cells were exposed for 1 h to DOX and S9788 simul-
taneously.
3. Cells were exposed for 1 h to DOX and S9788 simul-
taneously, washed and then further exposed to S9788
alone for 24 h.
4. Cells were exposed for 1 h to DOX and S9788 simul-
taneously, washed and then further exposed to S9788
alone for 6 h.
5. Cells were first exposed for 24 h to S9788 alone, then
for 1 h to DOX and S9788 simultaneously and then
washed.
6. Cells were first exposed for 6 h to S9788 alone, then for
1 h to DOX and S9788 simultaneously and then
washed.
7. Cells were exposed for 24 h to S9788 alone, then to
DOX and S9788 for 1 h, then washed and exposed to
S9788 alone for 24 h more.
S9788 was compared with VRP using the same protocols
of incubation.
Expression ofresults
Results were expressed as percentage cell survival, and the
concentration of DOX which causes 50% growth inhibition
with respect to controls (IC50) was determined. For the
MCF7 cell line, a sensitisation factor (Sen. F) was defined as
the ratio of the IC50 with DOX and modulator to the IC50
with DOX alone. The resistance of the MCF7/DOX cell line
relative to the corresponding sensitive parental line MCF7
was expressed as the fold resistance [resistance factor (Res.
F) = IC50 cytotoxic in resistant line/ICm cytotoxic in sensitive
line]. The activity of S9788 or VRP was expressed as fold
reversion [reversal factor (Rev. F) = IC50 cytotoxic alone/IC50
cytotoxic + modulator].
DOX accumulation studies
Cellular accumulation of DOX was determined by incubation
of 2 x 106 cells plated I day before in a 100 mm2 Petri dish in
complete growth medium at 37°C. Both cell lines were
incubated at their IC50 values of DOX. For protocols 5 and
7, cells were preincubated for 24 h with S9788 alone before
DOX addition. Incubation of cells with the anti-cancer drug
was stopped at different times (10, 20, 30 and 60 min). Cells
were washed twice in ice-cold phosphate-buffered saline
(PBS), trypsinised, and the cell-associated drug concentra-
tions were determined by high-performance liquid
chromatography (HPLC) with fluorimetric detection after
sonication and extraction by organic solvent as described
elsewhere (Muller et al., 1993). Values were expressed as ng
of associated drug per 106 cells.
Three independent experiments were performed in tripli-
cate.
DOX efflux studies
Cells were incubated with DOX for 1 h as described in the
drug accumulation section. At the end of the incubation, cells
were placed on ice and washed once with ice-cold PBS. Then,
drug-free RPMI complete medium was added, and cells were
reincubated at 37°C. S9788 was incubated with the cells
during the release study as described in schedules 3, 4 and 7.
At the end of each period of time (1, 2, 6 and 24 h), cells
Table I Effects of S9788 on the sensitivity of the MCF7/DOX cell line to doxorubicin according to different
schedules
MCF/DOX Reversal Resistance
Schedule Drug and length of exposure IC50 (JAM) factor factor
I DOX lh 190±6.3
2 DOX I h+ 25.86 1.72 7.34 0.39 117.5
S9788 I h
3 DOX 1 h + S9788 24 h 2.93 ± 0.36 65.6 15.4 15.4
S9788 1 h
4 DOX lh+ S9788 6h 4.13±0.36 39.8±7.5 21.7
S9788 1 h
5 S9788 24 h DOX lh+ 10.69 4.63 20.8 7.0 53.4
S9788 1 h
6 S9788 6 h DOX 1 h+ 10.44 2.51 19.4 5.66 54.9
S9788 1 h
7 S9788 24h DOX lh+ S9788 24h 1.72 0.90 105 10 10.75
S9788 1 h
IC50 values are shown as the mean ± s.d. calculated from data obtained in three experiments, each based on
determinations in triplicate. Reversal factors (Rev. F) were calculated as IC50 without modifier/IC50 with modifier.
Resistance factors (Res. F) were calculated as ICs for resistant cells/IC50 for sensitive cells.870 A.-M. JULIA et al.
washed, trypsinised and counted as previously described.
Efflux at each time point was determined by the method
described in the section on DOX accumulation.
Three independent experiments were performed in trip-
licate.
Results
Effect ofS9788 on circumvention ofmultidrug resistance in
MCF7/DOX cell line
The results obtained with the new MDR modulator using
different protocols on sensitive and resistant MCF7 cell lines
are summarised in Table I. In the parental MCF7 cell line,
S9788 had no effect on DOX cytotoxicity: the Sen. F was
almost constant at about 1.
When MCF7/DOX cells were incubated simultaneously
with DOX and S9788 for 1 h, Rev. F was low (7.3). This
factor increased (Rev. F = 20.8) after an S9788 preincubation
of 24 h. It reached 65.6 when S9788 was present during and
24 h after the exposure to DOX. Finally, the greatest effect of
S9788 was obtained when a preincubation and a post-
incubation of 24 h were carried out (Rev. F = 105). However,
the circumvention of resistance was still incomplete in the
MCF7/DOX subline, the residual resistance factor being
10.7.
Pre- and post-incubation of 6 h before and after DOX
incubation led to reversal factors of 19.4 and 39.8 respec-
tively (protocols 6 and 4) (Table I).
When considering exposure of cells to S9788 by the prod-
uct concentration x time, it is noteworthy that, for an equal
exposure, the presence of S9788 in the culture medium during
and after the end of incubation with DOX was more effective
than its presence before incubation with DOX (Figure 1).
Comparison with verapamil
The effects of S9788 and VRP on DOX cytotoxicity are
compared in Figure 2 in a series of charts. S9788 was a much
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Figure 1 Effects of simultaneous and sequential exposure to
S9788 on the sensitivity to DOX of the MCF7/DOX cell line.
The areas under the curves of S9788 were calculated by the
product concentration (1 gM) x time of exposure (1, 7, 25 or
49 h). Reversal factors (Rev. F) were calculated as IC50 without
modifier/IC50 with modifier. IC50 values necessary for obtaining
the reversal factor were calculated from data obtained in three
experiments, each based on determinations in triplicate. ( Ei)
Cells were exposed to S9788 during (1 h) and after incubation (6
or 24 h) with DOX. ( ER Cells were exposed to S9788 before (6
or 24 h) and during (1 h) incubation with DOX. (L ) Cells
were exposed to S9788 during (1 h) incubation with DOX. ( _ )
Cells were exposed to S9788 before (24 h), during (1 h) and after
(24 h) incubation with DOX.
more potent reversal agent ofmultidrug resistance than VRP.
Like S9788, VRP had no effect on the sensitive cell line
MCF7. On the MCF7/DOX cells, the reversal factors
obtained with this modulator were less than those obtained
with S9788 in all protocols tested with the same concentra-
tions of modulator (1 JIM). A residual resistance factor of
12.5 was observed for VRP in the optimum schedule tested
(see schedule 7).
Accumulation ofDOX in MCF7/DOX cells according to the
differentprotocols ofexposure to S9788
Cells were incubated in growth medium containing DOX
alone at its IC50 concentration or in the presence of 1 JAM
S9788 for 1 h. In another experiment, cells that had been
previously incubated for 24 h with 1 JIM S9788 were then
incubated with both compounds for 1 h. Enhanced
accumulation of DOX in the presence of S9788 with MCF7/
DOX was evident, but in no case did S9788 completely
restore the DOX accumulation to the level observed in the
MCF7 cells (Figure 3). At the end of 1 h exposure, the levels
of DOX were 4-fold greater in S9788-treated cells than in
untreated cells. Preincubating cells for 24 h with S9788 also
enhanced the DOX accumulation by 1.5-fold. Moreover, the
kinetics of DOX accumulation differed in that there was a
gradual increase in cell-associated DOX in MCF7/DOX cells
in the presence of S9788, whereas maximum accumulation by
MCF7/DOX was reached within 1 h without modulator.
Effects ofS9788 on DOX release
The presence of 1 gM S9788 in the culture medium after the
end of DOX exposure markedly reduced DOX release from
MCF7/DOX cells. In cells treated with S9788 during and not
after DOX exposure, the DOX efflux was equivalent to that
shown in MCF7/DOX cells (Figure 4).
Finally, the cytotoxic activity of DOX was related to
'effective drug exposure', which was defined as the area under
the curve of plots of cell-associated DOX versus time. Figure
5 illustrates the effects of DOX cell exposure on the ICs of
MCF7/DOX cells according to the different schedules tested.
A logarithmic relationship was estbalished between these two
parameters (r = 0.97): S9788 increases effective drug
exposures to DOX, and this increase is related to the
cytotoxic effect of this drug.
Discussion
In this work, we have examined and compared the effects of
different schedules of exposure to two MDR reversal agents,
VRP and S9788, on the cytotoxicity of DOX on an MDR
cell line. Since the demonstration by Tsuruo et al. (1981) of a
reversal of the MDR phenotype in P388 leukaemia by
incubation with VRP and DOX, there have been numerous
reports of synergism between these two drugs. In order to
mimic clinical situations in which DOX is currently
administered by i.v. bolus, in our study cells were exposed to
this drug for 1 h. The study of Cairo et al. (1989) has pointed
out the importance of a careful consideration of the peak
plasma level and the pharmacokinetics of drugs to be used in
reversal of multidrug resistance. In the case of S9788, the
early pharmacokinetic data obtained during phase I clinical
trials (Khayat et al., 1993; Lucas et al., 1993) showed that a
peak plasma level of 2 JM is reached at the maximum
tolerated dose. Similar levels have been obtained in clinical
trials with high doses of VRP (Ozols et al., 1987; Cairo et al.,
1989). Under these conditions, the use of MDR modulator
concentrations of 1 JIM in in vitro experiments seems to be
relevant to the clinical situations. Our results confirmed the
ability of S9788 to reverse MDR (Leonce et al., 1992; Pierre
et al., 1992; Perez et al., 1993). These previous studies dem-
onstrated that MDR modulation by S9788 is dose dependent
in all the cell lines studied. Our study showed that theCIRCUMVENTION OF MDR BY S9788 871
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Figure 2 Comparison of reversal properties of gM S9788 and 1 gM verapamil in the MCF7/DOX cell line according to different
protocols of incubation with the reversal agent. MCF7 and MCF7/DOX were incubated with different concentrations of DOX in
the presence or absence of modulators. Percentage cell survival (± s.d.) was plotted from data obtained in three experiments, each
based on determinations in triplicate. Schedule 2: cells were exposed for h to different concentrations of DOX and 1 JiM S9788 or
verapamil simultaneously. Schedule 3: cells were exposed for h to different concentrations of DOX and 1 JiM S9788 or verapamil
simultaneously, washed and then exposed to S9788 or verapamil for 24 h. Schedule 5: cells were exposed for 24 h to jAM S9788 or
verapamil, then for h to different concentrations of DOX and I JLM S9788 or verapamil simultaneously. Schedule 7: cells were
exposed for 24 h to S9788 or verapamil, then to different concentrations of DOX and I gAM S9788 for h, then washed to remove
DOX and exposed to S9788 or verapamil only for 24 h. (0) MCF7; (@) MCF7/DOX without modulator; (-) MCF7/DOX with
I jAM S9788; (0) MCF7/DOX with jAM verapamil.
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Figure 3 Effects of different exposures to S9788 on DOX
accumulation in MCF7 and MCF7/DOX cells. Cells were incu-
bated for 1 h with DOX at its IC5o concentration either without
S9788 [sensitive cells (-); resistant cells (-)] or with FM S9788
using two different protocols: simultaneous incubation for h
(0) and preincubation of the modulator for 24h (0). Cell-
associated drug was determined by HPLC after sonication and
extraction. Values shown are the mean ± s.d. calculated from
data obtained in three experiments, each based on triplicate
determinations.
optimum schedule for modulating MDR consisted in a 24 h
pre-and post-incubation with 1 gM S9788 and concomitant
exposure to S9788 and DOX. However, this regimen has not
been used in the first clinical trials (Khayat et al., 1993). We
have also shown that, for an equal concentration x time
exposure, S9788 activity is schedule dependent: the post-
incubation was more important for the activity (when com-
paring a pre with a post DOX incubation with S9788, the
reversal factor was higher in the case of a post-incubation).
Similar results have been obtained with VRP (Cass et al.,
1989; Toffoli et al., 1993). Moreover, the results presented
here show that there is no direct relationship between in-
creasing post-incubation exposure to S9788 and reversal of
MDR resistance: an exposure of 24 h to 1 JAM S9788 (corres-
ponding to a C x T= 25 JLM x h) led to a reversal factor of
65 ± 7, whereas an exposure of 6 h (C x T = 7 JiM x h) pro-
duced a Rev. F of 40 ± 7. This C x T of 7 JM xh could be
of clinical relevance, since the human pharmacokinetic data
showed that such an AUC could be reached in clinical trials
combining a loading dose and a continuous infusion of
S9788 following cytotoxic drug administration. All these
results might be due to the cellular pharmacokinetics of
S9788: Perez et al. (1993) have shown in the sensitive and
resistant human lung carcinoma SI cell line that approxi-
mately 50% of drug is removed from the cells in about 1 h of
incubation in modulator-free medium; then, after 6 h of
incubation, the intracellular concentration plateaus and 20 h
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Figure 4 Effects of different exposures to S9788 on DOX release
in MCF7 and MCF7/DOX cells. Cells were incubated for 1 h
with DOX at its IC50 concentration under the following condi-
tions: (O) sensitive cells or (O) resistant cells without S9788; (0)
MCF7/DOX cells simultaneously incubated with 1 JAM S9788 and
DOX for I h; (0) MCF7/DOX cell preincubated for 24 h with
1 JAM S9788, then incubated with S9788 and DOX simultaneously
for 1 h. (A) simultaneously incubated with S9788 and DOX for
1 h and then reincubated for 24 h with 1 jLM S9788; (A) MCF7/
DOX cells preincubated for 24 h with 1 llM S9788, then incubated
with S9788 and DOX simultaneously for 1 h and then rein-
cubated for 24 h with 1 JAM S9788. Cell-associated DOX was
determined by HPLC after sonication and extraction. Values
shown are the means calculated from data obtained in three
experiments, each based on determinations in triplicate. The s.d.
values obtained were always within ± 10% of the means.
after the cells are washed the retention of S9788 is about
20% of the initial concentration.
Our study confirmed that S9788 is a more potent
modulating agent than VRP, whatever the schedule of
exposure of the cells to the reversal agent. Compared with
VRP, the superior effect of S9788 may be explained, in part,
by its higher affinity for Pgp, as suggested by its greater
ability to inhibit [3H]azidopidine photolabelling (Leonce et
al., 1992) and in part by the difference in cellular phar-
macokinetics of these drugs: for equal extracellular concent-
rations (5 JM), S9788 was accumulated and retained by cells
to a greater extent than VRP (Perez et al., 1993). However,
even when using the optimum schedule, reversal of resistance
was incomplete in the MCF7/DOX cell line: residual resis-
tance factors of 10 and 12.5 were observed for S9788 and
VRP respectively. One explanation is the fact that the
MCF7/DOX cell line expresses a very high degree of MDR
and exhibits several mechanisms of resistance including mdrl
gene overexpression, increased antioxidant defence system
and topoisomerase I and II modifications (Batist et al., 1986).
On the other hand, it has been established that the activity of
S9788 depends on both the MDR cell line used (i.e. the Pgp
level or the resistance factor) and the method of selection of
resistance (Pierre et al., 1992). The method of selection of
resistance seems to be very important since the reversal of
resistance to DOX in all cell lines obtained by selection on
DOX was incomplete. By contrast, a human mdrl-transfected
cell line showed complete reversal by S9788 on vincristine
resistance, confirming the mechanism of action of the com-
pound (Pierre et al., 1992).
Co-administration of MDR modulators with the various
anti-cancer drugs associated with the MDR phenotype often
results in increased net accumulation of drug in MDR cell
lines (Luk & Tannock, 1989; Bruno & Slate, 1990; Huet et
al., 1993). In the MCF7/DOX cell line, we showed that the
cellular content of DOX increased when S9788 and DOX
were co-administered over a 1 h period. In addition, the loss
of DOX from cells was reduced when S9788 was present
Figure 5 Effects of various exposures of cells to DOX (concent-
ration x time) on the IC50. The areas under the curves (Figures 3
and 4) of cellular drug content versus time (from 0 to 25 h) were
calculated to obtain a measure of the effective drug exposure
during the accumulation and release phases. Cellular drug con-
tent versus time values are means ± s.d. of three independent
experiments, each based on determinations in triplicate. IC50
values are those expressed in Table I. (LII) Schedule 1: cells
were exposed for 1 h to DOX.(() Schedule 2: cells were
exposed for 1 h to DOX IC50 and 1 JLM S9788 simultaneously.
( EIil) Schedule 3: cells were exposed for 1 h to DOX IC50 and
1 JAM S9788 simultaneously, washed and then exposed to S9788
for 24 h. ( ) Schedule 4: cells were exposed for 1 h to DOX
ICm and 1 JAM S9788 simultaneously, washed and then exposed to
S9788 for 6 h. (1 ) Schedule 5: cells were exposed for 24 h to
1 JAM S9788, then for 1 h to ICm DOX and 1 JM S9788 simul-
taneously. ( M ) Schedule 7: cells were exposed for 24 h to
S9788, then to DOX IC50 and 1 JLM S9788 for 1 h, washed to
remove DOX and then exposed with S9788 only for 24 h.
during the release phase. Thus, the reversal of resistance after
short-term DOX. exposures was the result not only of
enhanced cellulag accumulation of DOX during DOX
exposure, but also of enhanced retention after transfer of
cells to DOX-free medium. These results confirmed that the
maximum efficacy of S9788 can be achieved by administra-
tion of S9788 both during and after administration of the
cytotoxic agent. Similar results have been found for VRP
(Cass et al., 1989). Moreover, the levels of intracellular DOX
have been shown to correlate with cell survival (Keizer et al.,
1989; Luk & Tannock, 1989), and our results are in agree-
ment with these data since a relationship was noted between
cell exposure to DOX and its cytotoxic effect; thus, the
reversal of resistance itself appears to depend directly on the
level of accumulation of DOX (Ganapathi et al., 1984;
Schuurhuis et al., 1989). Other authors have shown (Huet et
al., 1993) that DOX accumulation alone may not predict
drug sensitivity; it may be necessary to consider subcellular
drug distribution. Since the DOX accumulation measured by
HPLC or by flow cytometry is a global detection, it is
difficult to identify the various intracellular compartments
containing DOX or, more precisely, the DOX molecules
involved in the cytotoxicity. Different reports studying the
intracellular distribution of DOX have shown that in paren-
tal cells fluorescence is predominantly nuclear, whereas in
resistant cells fluorescence is distributed in the cytoplasm in
distinct punctate regions (Keizer et al., 1989; Schuurhuis et
al., 1989; Gervasoni et al., 1991). Other authors have
reported that MDR cells exhibit alterations in membrane
traffic processes, suggesting endosomal drug trapping
(Sehested et al., 1987): DOX could be trapped in vesicles in
MDR cells, a phenomenon that would not occur in sensitive
cells. It has been shown, using laser scanning confocal
fluorescence imaging microscopy, that the presence of a resis-
tance modulator such as VRP is able to increase the intensity
Time (h)
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of fluorescence of DOX in MDR lines, particularly in the
nucleus (Barrand et al., 1993; Coley et al., 1993). Such a
technique might be applied to S9788 to confirm the
hypothesis expressed by Huet et al. (1993) that this drug
could be able to decrease the intracellular IC50 independently
of its efficiency in restoring DOX accumulation, thus revers-
ing intracellular drug tolerance. Such a drug might be able to
segregate DOX in subcellular compartments from which it
could not reach its nuclear targets.
In conclusion, we have compared the efficacy of various
schedules of administration of S9788 in combination with
DOX in an MCF7/DOX cell line. The optimum resistance
reversion was obtained when cells were incubated with S9788
before, during and after DOX exposure. However, to be
compatible with clinical situations, a- post-incubation of at
least 6 h with the modulator is recommended. The modula-
tion efficiency of this MDR reversal agent was correlated
with the DOX cellular content versus time.
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